ArticleBMC infectious diseases2026
Development and evaluation of a real-time RT-PCR assay for Mammarenavirus guanaritoense virus detection.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Mammarenavirus guanaritoense (formerly Guanarito virus, GTOV) is an important etiological agent of an emergent disease with a high mortality rate, namely Venezuelan hemorrhagic fever (VHF). Traditionally, VHF is an important public health problem and is a mandatory reportable disease. Moreover, global interconnection has increased the probability of worldwide spread of GTOV. Therefore, national healthcare organizations need tools for the management of GTOV-associated risks. These tools should definitely include diagnostic kits based on real-time reverse transcription PCR (RT-PCR) because it is the most suitable method for the diagnosis of viral hemorrhagic fever diseases. Here, we describe a real-time RT-PCR assay for the detection of GTOV. This assay was developed and evaluated using armored positive control particles (ARC). The LOD of the assay is in the range 1–2.5 × 102 RNA copies/mL on the CFX96 PCR plate machine and is in the range 1–2.0 × 103 RNA copies/mL on the Rotor-Gene Q PCR rotary machine. Our assay was evaluated using positive GTOV samples from the collection of the Instituto Nacional de Higiene “Rafael Rangel”, Caracas, Venezuela (INHRR). The assay provides a fast and sensitive tool for GTOV detection. The high specificity and sensitivity of the assay make it useful for clinical and epidemiological investigations in the field of VHF and their etiological agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.